Abstract:Background: Celastrol, an important extract of Tripterygium wilfordii , shows strong antitumor activity in a variety of tumors including nasopharyngeal carcinoma (NPC). However, little is known about its targets in NPC. We aimed to screen the key gene targets of Celastrol in the treatment of NPC by means of in silico analyses (including network pharmacology and molecular docking) and experimental evaluations. Methods: The main target genes of Celastrol and the genes related to NPC were obtained by retrieving the relevant biological databases, and the common targets were screened. Protein-protein interaction analysis was used to screen the hub genes. Then, a “compound-target-disease” network model was created and molecular docking was used to predict the binding of Celastrol to the candidate hub proteins. Afterward, the expression changes of the candidate genes under the administration of Celastrol were verified in vitro and in vivo . Results: Sixty genes common to Celastrol and NPC were screened out, which may be related to numerous biological processes such as cell proliferation, apoptosis, and tube development, and enriched in various pathways such as PI3K- Akt, EGFR tyrosine kinase inhibitor resistance, and Apoptosis. The tight binding ability of the candidate hub proteins (TNF, VEGFA, and IL6) to Celastrol was predicted by molecular docking [Docking energy: TNF, −6.08; VEGFA,−6.76; IL6,−6.91(kcal/mol)]. In vitro experiments showed that the expression of TNF and VEGFA decreased while the expression of IL6 increased in NPC cells (CNE2 and HONE1) treated with Celastrol. In vivo experiments suggested that Celastrol significantly reduced the weight and volume of the transplanted tumors in tumor-bearing mice in vivo . The expression of TNF, VEGFA, and IL6 in the transplanted tumor cells could be regulated by using Celastrol, and the expression trends were consistent with the in vitro model. Conclusion: Several gene targets have been filtered out as the core targets of Celastrol in the treatment of NPC, which might be involved in a variety of signaling pathways. Hence, Celastrol may exert its anti-NPC activity through multiple targets and multiple pathways, which will provide new clues for further research. Future experiments are warranted to validate the findings.

Proteomic Analysis of the Molecular Mechanism of Lovastatin Inhibiting the Growth of Nasopharyngeal Carcinoma Cells.

The mechanism of lovastatin in suppressing the proliferation of esophageal squamous cell carcinoma based on proteomics

Statins enhance anti-tumro effect of sub reoylanilide hydroxamic acid on human non-small cell lung carcinoma cells

Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma.

An Overview On The Biological Activity And Anti-Cancer Mechanism Of Lovastatin

Lovastatin-mediated Pharmacological Inhibition of Formin Protein DIAPH1 Suppresses Tumor Immune Escape and Boosts Immunotherapy Response

Lovastatin Inhibits Cell Proliferation and Migration in Cholangiocarcinoma Cell Line QBC939

Hexokinase 2 is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells

Effects of Lovastatin on Differentially Expressed Genes in HepG2 Cells

Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma

[Effects of Clinically Effective Dose of Lovastatin on Prostate Cancer PC3 Cells].

BRCA1 Overexpression Sensitizes Cancer Cells to Lovastatin Via Regulation of Cyclin D1-CDK4-p21WAF1/CIP1 Pathway: Analyses Using a Breast Cancer Cell Line and Tumoral Xenograft Model

Lovastatin Induces Apoptosis of HepG-2 Cells by Activating ROS-dependent Mitochondrial and ER Stress Pathways.

Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.

Anticancer Effects of Lanostane Against Human Gastric Cancer Cells Involves Autophagy, Apoptosis and Modulation of M-Tor/pi3k/akt Signalling Pathway.

Weighted Gene Co-Expression Network Analysis and Connectivity Map Identifies Lovastatin As a Treatment Option of Gastric Cancer by Inhibiting HDAC2.

Resveratrol Inhibits Nasopharyngeal Carcinoma (NPC) by Targeting the MAPK Signaling Pathway

Exploration of the effect of Celastrol on protein targets in nasopharyngeal carcinoma: Network pharmacology, molecular docking and experimental evaluations

Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis

Ott_a_237693 2057..2066

Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma.